Open AccessP957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO‐HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT
Author(s) -
Tilmont R.,
YakoubAgha I.,
Eikema D.J.,
Zinger N.,
Haenel M.,
Schaap N.,
Herrera Arroyo C.,
Schuermans C.,
Bethge W.,
Engelhardt M.,
Kuball J.,
Michieli M.,
Schub N.,
Wilson K. M. O.,
Bourhis J. H.,
Mateos M. V.,
Robin N.,
Jost E.,
Kröger N.,
Moraleda J. M.,
Sica S.,
Hayden P. J.,
Beksac M.,
Schönland S.,
Manier S.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846696.43332.f6
Subject(s) - carfilzomib , lenalidomide , medicine , multiple myeloma , context (archaeology) , regimen , dexamethasone , oncology , population , transplantation , progression free survival , surgery , chemotherapy , paleontology , environmental health , biology